Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Love The One You’re With: BMS Pays Exelixis $240M Upfront In New Cancer Drug Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Exelixis re-partners with long-term collaborator BMS the same late-stage XL184 that GSK rejected less than two months earlier.
Advertisement

Related Content

Exelixis Reorganizes R&D And Cuts Its Workforce By 40 Percent
Reimbursement Risks Driving Contingency-Based Deals, GSK Exec Says
Reimbursement Risks Driving Contingency-Based Deals, GSK Exec Says
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2008
GSK, Dynavax To Partner On TLR Compounds In Autoimmune, Inflammatory Disease
Oncology Candidates Stream From Exelixis Discovery Platform
Exelixis Hopes To Avoid The Whole Capital Mess By Peddling Its Pipeline
GSK/Exelixis: The End of an Era
GSK/Exelixis: The End of an Era
Lilly Snatches ImClone Away From Bristol

Topics

Advertisement
UsernamePublicRestriction

Register

PS067119

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel